Correction of glycogen storage disease type III with rapamycin in a canine model

Journal of Molecular Medicine

Volumn 92, Issue 6, 2014, Pages 641-650

  Yi, Haiqing ^a   Brooks, Elizabeth D ^a   Thurberg, Beth L ^b   Fyfe, John C ^c   Kishnani, Priya S ^a   Sun, Baodong ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SANOFI   (France)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Glycogen accumulation; Glycogen storage disease type III; Hepatic fibrosis; Rapamycin

Indexed keywords

GLUCOSE TRANSPORTER 1; GLYCOGEN SYNTHASE; PROTEIN S6; RAPAMYCIN; GLYCOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL DOG; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; GLYCOGEN LIVER LEVEL; GLYCOGEN MUSCLE LEVEL; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN SYNTHESIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER WEIGHT; LOW DRUG DOSE; MUSCLE BIOPSY; MYOFIBROBLAST; NONHUMAN; STELLATE CELL; TREATMENT DURATION; UPREGULATION; ANIMAL; DOG; GLYCOGEN STORAGE DISEASE TYPE III; LIVER CIRRHOSIS; METABOLISM;

ANIMALS; DOGS; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE III; LIVER CIRRHOSIS; SIROLIMUS;

EID: 84901585492     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1127-4     Document Type: Article

References (36)

1. Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, Chung WK, Desai DM, El-Gharbawy A, Haller R et al (2010) Glycogen storage disease type III diagnosis and management guidelines. Genet Med Off J Am Coll Med Genet 12:446-463
2. Chen YT, Kishnani PS, Koeberl DD (2009) Glycogen storage diseases. In: Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A (eds) Scriver's online metabolic & molecular bases of inherited disease. McGraw-Hill, New York
3. Demo E, Frush D, Gottfried M, Koepke J, Boney A, Bali D, Chen YT, Kishnani PS (2007) Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol 46:492-498
4. Cosme A, Montalvo I, Sanchez J, Ojeda E, Torrado J, Zapata E, Bujanda L, Gutierrez A, Arenas I (2005) Type III glycogen storage disease associated with hepatocellular carcinoma. Gastroenterol Hepatol 28:622-625
5. Haagsma EB, Smit GP, Niezen-Koning KE, Gouw AS, Meerman L, Slooff MJ (1997) Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinoma. The Liver Transplant Group. Hepatology 25:537-540
6. Coleman RA, Winter HS, Wolf B, Chen YT (1992) Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features. J Inherit Metab Dis 15:869-881
7. Lucchiari S, Santoro D, Pagliarani S, Comi GP (2007) Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/edited by the Gaetano Conte Academy for the study of striated muscle diseases 26:72-74
8. Momoi T, Sano H, Yamanaka C, Sasaki H, Mikawa H (1992) Glycogen storage disease type III with muscle involvement: reappraisal of phenotypic variability and prognosis. Am J Med Genet 42:696-699
9. Miller CG, Alleyne GA, Brooks SE (1972) Gross cardiac involvement in glycogen storage disease type 3. Br Heart J 34:862-864
10. Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV (1984) Cardiac involvement in glycogen storage disease III: morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol 53:980-981
11. Moses SW, Wanderman KL, Myroz A, Frydman M (1989) Cardiac involvement in glycogen storage disease type III. Eur J Pediatr 148:764-766
12. Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV (1997) Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. Am J Cardiol 79:834-838
13. Yi H, Thurberg BL, Curtis S, Austin S, Fyfe J, Koeberl DD, Kishnani PS, Sun B (2012) Characterization of a canine model of glycogen storage disease type IIIa. Dis Model Mech 5:804-811. doi: 10.1242/dmm.009712
14. Sengupta S, Peterson TR, Sabatini DM (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40:310-322
15. Rostaing L, Kamar N (2010) mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 23:133-142
16. Polak P, Hall MN (2009) mTOR and the control of whole body metabolism. Curr Opin Cell Biol 21:209-218
17. Tsang CK, Qi H, Liu LF, Zheng XF (2007) Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12:112-124
18. Goberdhan DC, Boyd CA (2009) mTOR: dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans 37:213-216
19. Dazert E, Hall MN (2011) mTOR signaling in disease. Curr Opin Cell Biol 23:744-755
20. Sipula IJ, Brown NF, Perdomo G (2006) Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metab Clin Exp 55:1637-1644
21. Varma S, Shrivastav A, Changela S, Khandelwal RL (2008) Long-term effects of rapamycin treatment on insulin mediated phosphorylation of Akt/PKB and glycogen synthase activity. Exp Cell Res 314:1281-1291
22. Ashe KM, Taylor KM, Chu Q, Meyers E, Ellis A, Jingozyan V, Klinger K, Finn PF, Cooper CG, Chuang WL et al (2010) Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol Genet Metab 100:309-315
23. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F (2011) Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 55:388-398
24. Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, Fletcher LM, Crawford DH (2009) Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 15:1315-1324
25. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J (2006) Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 45:786-796
26. Biecker E, De Gottardi A, Neef M, Unternahrer M, Schneider V, Ledermann M, Sagesser H, Shaw S, Reichen J (2005) Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 313:952-961
27. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, Norton P, Zern MA (1999) Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117:1198-1204
28. Sun B, Fredrickson K, Austin S, Tolun AA, Thurberg BL, Kraus WE, Bali D, Chen YT, Kishnani PS (2013) Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III. Mol Genet Metab 108:145-147
29. Lynch CM, Johnson J, Vaccaro C, Thurberg BL (2005) High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J Histochem Cytochem Off J Histochem Soc 53:63-73
30. Douillard-Guilloux G, Raben N, Takikita S, Batista L, Caillaud C, Richard E (2008) Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet 17:3876-3886
31. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J et al (2007) FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 6:458-471
32. Sridharan S, Jain K, Basu A (2011) Regulation of autophagy by kinases. Cancers 3:2630-2654
33. Safadi R, Friedman SL (2002) Hepatic fibrosis - role of hepatic stellate cell activation. Med Gen Med 4:27
34. Lee UE, Friedman SL (2011) Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25:195-206
35. Sacks SH (1999) Rapamycin on trial. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc 14:2087-2089
36. Morelon E, Mamzer-Bruneel MF, Peraldi MN, Kreis H (2001) Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc 16:18-20